H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Galapagos NV (GLPG) today and set a price target of $150. The company’s shares opened today at $112.58.
Chattopadhyay said:
“Valuation and risks to our investment thesis. Our 12-month, $150 price target on shares of Galapagos is derived from a 13- year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.34, terminal growth rate of -3.0%, risk premium of 4.93%, calculated WACC of 9.3%, and tax rate of 20% beginning in FY 2025. (11%) together make up 88% of our value, with the remainder derived from the probability-adjusted, filgotinib-associated milestone payments.”
According to TipRanks.com, Chattopadhyay is a 2-star analyst with an average return of 0.3% and a 45.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
Currently, the analyst consensus on Galapagos NV is a Strong Buy with an average price target of $136.25, representing a 21.0% upside. In a report issued on April 26, Cantor Fitzgerald also maintained a Buy rating on the stock with a $130 price target.
See today’s analyst top recommended stocks >>
Based on Galapagos NV’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $17.07 million. In comparison, last year the company had a GAAP net loss of $45.82 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.